Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa-Reference-Cited by-同舟云学术

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

Published:2012-03-13 Issue:3 Volume:7 Page:e32144
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Levison Julie H.,Orrell Catherine,Gallien Sébastien,Kuritzkes Daniel R.,Fu Naishin,Losina Elena,Freedberg Kenneth A.,Wood Robin

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. Country Fact Sheets: South Africa.,2010

2. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa.;L Long;AIDS,2010

3. Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: A Public Health Approach,2007

4. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.;C Orrell;Antivir Ther,2009

5. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.;S Walmsley;N Engl J Med,2002

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV Drug Resistance Mutations and Subtype Profiles among Pregnant Women of Ho Chi Minh City, South Vietnam;Viruses;2023-09-27

2. Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia;Infection and Drug Resistance;2023-07

3. Treatment-Experienced Patients on Third-Line Therapy: A Retrospective Cohort of Treatment Outcomes at the HIV Advanced Treatment Centre, University Teaching Hospital, Zambia;AIDS Research and Human Retroviruses;2022-10-01

4. Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial;Journal of the International AIDS Society;2022-06

5. HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa;Journal of Global Antimicrobial Resistance;2021-11